The genetics of kidney transplantation

[1]  D. Min,et al.  Genetic and Clinical Risk Factors of New-Onset Diabetes After Transplantation in Hispanic Kidney Transplant Recipients , 2011, Transplantation.

[2]  E. Lerut,et al.  Expression of CYP3A5 and P-glycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity , 2011, Transplantation.

[3]  M. Rocco,et al.  The APOL1 Gene and Allograft Survival after Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  Meenakshi Verma,et al.  Advances of genomic science and systems biology in renal transplantation: a review , 2011, Seminars in Immunopathology.

[5]  Y. Kim,et al.  Genetic Predisposition of Donors Affects the Allograft Outcome in Kidney Transplantation; Polymorphisms of Stromal-Derived Factor-1 and CXC Receptor 4 , 2011, PloS one.

[6]  Fatih Ozsolak,et al.  RNA sequencing: advances, challenges and opportunities , 2011, Nature Reviews Genetics.

[7]  H. Haslacher,et al.  Genotypic diversity of complement component C4 does not predict kidney transplant outcome. , 2011, Journal of the American Society of Nephrology : JASN.

[8]  M. Fromm,et al.  SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. , 2010, Pharmacogenomics.

[9]  Thomas Werner,et al.  Next generation sequencing in functional genomics , 2010, Briefings Bioinform..

[10]  J. Bluestone,et al.  Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia , 2010, Current opinion in organ transplantation.

[11]  P. Marquet,et al.  Donor P‐gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long‐Term Follow‐Up , 2010, Clinical pharmacology and therapeutics.

[12]  M. Loriot,et al.  Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing , 2010, Clinical pharmacology and therapeutics.

[13]  David B Goldstein,et al.  Screening the human exome: a comparison of whole genome and whole transcriptome sequencing , 2010, Genome Biology.

[14]  G. La Manna,et al.  Cardiovascular Disease in Kidney Transplant Recipients: The Prognostic Value of Inflammatory Cytokine Genotypes , 2010, Transplantation.

[15]  M. Simmonds,et al.  Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. , 2010, JAMA.

[16]  A. Goldfarb-Rumyantzev,et al.  Genetic predictors of acute renal transplant rejection. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  M. Droździk,et al.  Association of calpain-10 gene polymorphism and posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus , 2010, The Pharmacogenomics Journal.

[18]  Gerhard Opelz,et al.  C3 polymorphisms and allograft outcome in renal transplantation. , 2009, The New England journal of medicine.

[19]  M. Deschamps,et al.  Influence of Cyclooxygenase‐2 (COX‐2) Gene Promoter Polymorphism −765 on Graft Loss After Renal Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  I. Tikhonova,et al.  Genetic diagnosis by whole exome capture and massively parallel DNA sequencing , 2009, Proceedings of the National Academy of Sciences.

[21]  D. Abramowicz,et al.  TCF7L2 polymorphism associates with new-onset diabetes after transplantation. , 2009, Journal of the American Society of Nephrology : JASN.

[22]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[23]  P. Tiberghien,et al.  G-765C COX-2 gene promoter polymorphism and risk of atherosclerosis after kidney transplantation. , 2009, Transplantation.

[24]  E. Coto,et al.  Pharmacogenetics of Calcineurin Inhibitors in Renal Transplantation , 2009, Transplantation.

[25]  N. Perico,et al.  ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. , 2009, Journal of the American Society of Nephrology : JASN.

[26]  K. Frazer,et al.  Human genetic variation and its contribution to complex traits , 2009, Nature Reviews Genetics.

[27]  Alexander S. Goldfarb-Rumyantzev,et al.  Genetic prediction of renal transplant outcome , 2008, Current opinion in nephrology and hypertension.

[28]  L. Weber,et al.  Long-Term Pharmacokinetics of Mycophenolic Acid in Pediatric Renal Transplant Recipients Over 3 Years Posttransplant , 2008, Therapeutic drug monitoring.

[29]  K. Lindpaintner,et al.  Association of four DNA polymorphisms with acute rejection after kidney transplantation , 2008, Transplant international : official journal of the European Society for Organ Transplantation.

[30]  V. Pravica,et al.  IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients , 2008, Clinical pharmacology and therapeutics.

[31]  M. Kim,et al.  A Polymorphism in the Zinc Transporter Gene SLC30A8 Confers Resistance Against Posttransplantation Diabetes Mellitus in Renal Allograft Recipients , 2008, Diabetes.

[32]  E. Lerut,et al.  CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal Recipients , 2007, Clinical pharmacology and therapeutics.

[33]  P. Beaune,et al.  Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. , 2007, Pharmacogenomics.

[34]  P. Beaune,et al.  Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. , 2006, Kidney international.

[35]  L. Ward,et al.  Polymorphisms at exon 4 of p53 and the susceptibility to herpesvirus types 6 and 1 infection in renal transplant recipients , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[36]  M. Deschamps,et al.  IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation. , 2006, Journal of the American Society of Nephrology : JASN.

[37]  K. F. el-Dahshan,et al.  Ketoconazole-Tacrolimus Coadministration in Kidney Transplant Recipients: Two-Year Results of a Prospective Randomized Study , 2006, American Journal of Nephrology.

[38]  M. Giral,et al.  Influence of graft characteristics on the outcome of kidney transplantation. , 2006, The New England journal of medicine.

[39]  R. Vaughan,et al.  Influence of donor C3 allotype on late renal-transplantation outcome. , 2006, The New England journal of medicine.

[40]  M. Deschamps,et al.  Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. , 2005, Kidney international.

[41]  B. Maes,et al.  Risk Factors for Cardiovascular Events After Successful Renal Transplantation , 2005, Transplantation.

[42]  H. Ackermann,et al.  ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. , 2005, Journal of the American Society of Nephrology : JASN.

[43]  M. Ghoneim,et al.  A PROSPECTIVE, RANDOMIZED STUDY OF COADMINISTRATION OF KETOCONAZOLE AND CYCLOSPORINE A IN KIDNEY TRANSPLANT RECIPIENTS: TEN-YEAR FOLLOW-UP , 2004, Transplantation.

[44]  S. Martinotti,et al.  A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. , 2004, JAMA.

[45]  L. Shaw,et al.  Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. , 1993, Journal of the American Society of Nephrology : JASN.

[46]  J. Thliveris,et al.  Toxicity of Cyclosporine Metabolites , 1990, Therapeutic drug monitoring.

[47]  M. Metzker.  Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[48]  H. McLeod,et al.  The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. , 2002, Pharmacogenomics.